Corante

About this author
Zack Lynch is author of The Neuro Revolution: How Brain Science Is Changing Our World (St. Martin's Press, July 2009).
He is the founder and executive director of the Neurotechnology Industry Organization (NIO) and co-founder of NeuroInsights. He serves on the advisory boards of the McGovern Institute for Brain Research at MIT, the Center for Neuroeconomic Studies, Science Progress, and SocialText, a social software company. Please send newsworthy items or feedback - to Zack Lynch.
Follow me on Twitter at @neurorev
Receive by email

GUEST AUTHOR ARCHIVES
In the Boston area?: Join us on June 11 for Startups and the Cloud, a free event on cloud computing with insights from Intuit founder Scott Cook and others

Brain Waves

« What's Your Brain Age - Take this 7 minute test | Main | Neuromarketing from the Inside »

June 23, 2008

An Anti-Shyness Drug

Email This Entry

Posted by Zack Lynch

is_shy_070824_ms.jpgThe King of Trust, Paul Zak, touts oxytocin as a potential drug for shyness: "Tests have shown that oxytocin reduces anxiety levels in users. It is a hormone that facilitates social contact between people. What's more, it is a very safe product that does not have any side effects and is not addictive." The article contends that millions of people in the UK suffer from shyness, and one-in-10 people say it seriously affects their daily life.

Comments (0) + TrackBacks (0) | Category: Emoticeuticals


POST A COMMENT

Thanks for signing in, . Now you can comment. (sign out)

(If you haven't left a comment here before, you may need to be approved by the site owner before your comment will appear. Until then, it won't appear on the entry. Thanks for waiting.)





Remember me?


EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
NIO Unveils Top 10 Neuroscience Trends for 2009
NIO CEO Media Tour in NYC Gets Results
O Neurocaster
Manuscript Sent to Japan
2009 Stem Cell Trendsetters in Neurology and Psychiatry
Mental Health Parity Legislation Passes within Financial Package
Holy Neurofinancial Meltdown Bernanke
Interest in Neuropolicy Grows